Wells Fargo initiated coverage on Metsera with a new price target
$MTSR
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2025 | $77.00 | Outperform | Leerink Partners |
| 6/20/2025 | $65.00 | Overweight | Wells Fargo |
| 2/25/2025 | $56.00 | Buy | Guggenheim |
| 2/25/2025 | $38.00 | Buy | BofA Securities |
| 2/25/2025 | Outperform | Evercore ISI |
4/A - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatment retention in both VESPER-1 and VESPER-3 trials Data support Phase 3 initiation in late 2025 NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i, a first-in-class fully biased, ultra-long acting GLP-1 receptor agonist (RA) with potential for monthly dosing. In VESPER-1, MET-097i demonstrated me
Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present clinical and preclinical data from its portfolio of next-generation ultra-long acting, scalable, and combinable therapies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held September 15-19, 2025, in Vienna, Austria. "As we progress our pipeline of ultra-long acting next-generation nutrient-stimulated hormone, or NuSH, therapies, we are encouraged by the opportunity to leverage our investigational medicines both as monotherapies and in comb
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
Leerink Partners initiated coverage of Metsera with a rating of Outperform and set a new price target of $77.00
Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00
Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00
8-K - Metsera, Inc. (0002040807) (Filer)
8-K - Metsera, Inc. (0002040807) (Filer)
10-Q - Metsera, Inc. (0002040807) (Filer)
Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb